drugset / Trial / NCT03154619

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers

NCT03154619

Phase 2 Active not recruiting 80 enrolled SerenaGroup, Inc. TR Therapeutics · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.

Timeline

Start
2016-11
Primary completion
2019-04-04
Completion
2021-04-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator beta-glucan Other / unclassified 0.1 % Topical

Indications